StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

N,N-Dimethyl-3-((1-(phenylmethyl)-1H-indazol-3-yl)oxy)-1-propanamin

Benzydamine

HCID 12555
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
642-72-8
Standard-SMILES
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12
InChIKey
CNBGNNVCVSKAQZ-UHFFFAOYSA-N
Summenformel
C19H23N3O
Durchschnittliche Molmasse
309,4 g/mol
Monoisotopische Masse
309,18411237

Überblick

Benzydamine is a member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties. It has a role as a central nervous system stimulant, a non-steroidal anti-inflammatory drug, an analgesic, a hallucinogen and a local anaesthetic. It is an aromatic ether, a member of indazoles and a tertiary amino compound. It is a conjugate base of a benzydamine(1+).

Namen und Bezeichner

Bevorzugter Name
Benzydamine
IUPAC
3-(1-benzylindazol-3-yl)oxy-N,N-dimethylpropan-1-amine
Lokaler Name
N,N-Dimethyl-3-((1-(phenylmethyl)-1H-indazol-3-yl)oxy)-1-propanamin
Englischer Name
Benzydamine
Summenformel
C19H23N3O
Molmasse
309.41

Namen und Synonyme

BENZYDAMINE642-72-8BenzidamineBenzindamineBencidaminaBenzydaminumBenzidaminaApo-Benzydamine1-Benzyl-3-(3-(dimethylamino)propoxy)-1H-indazole1-Benzyl-3-[3-(dimethylamino)propoxy]-1H-indazole4O21U048EF{3-[(1-benzyl-1H-indazol-3-yl)oxy]propyl}dimethylamine
Weitere Namen anzeigen
BenzyaMineAURORA KA-7514Benzydamine (>90%)Benzydamine USP/EP/BPBenzydamine, 10 mM in DMSOBenzydamine (base and/or unspecified salts)INDAZOLE,1-BENZYL-3-(3-(DIMETHYLAMINO)PROPOXY)-
1-Propanamine, N,N-dimethyl-3-((1-(phenylmethyl)-1H-indazol-3-yl)oxy)-DTXSID7047859CHEBI:945631-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-(3-((1-benzyl-1H-indazol-3-yl)oxy)propyl)dimethylamineNovo BenzydaminePMS Benzydamineratio Benzydamine

Datenbank-Bezeichner

CAS

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
3,9
Polarare Oberfläche (TPSA)
30,3 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
7
Schwere Atome
23
Formalladung
0
Komplexität
344

Experimentelle und physikochemische Eigenschaften

Drugs · 3 Einträge

Synthetic Cannabinoids

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

SolubilityMiscible
Human DrugsPharmaceuticals
Melting Point320°F
Dissociation Constants9.27
Collision Cross Section174.24 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
167 · 167-170 °C
Siedepunkt
0.05 · bp0.05 160°
Dichte
1.1106 · 1.1106 (rough estimate)
Brechungsindex
1.59 · 1.5900 (estimate)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Gefahrenhinweise

Other Safety InformationIMAP assessments - 1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Sicherheitsdaten

wgk
WGK 3
Toxizität
LD50 orl-rat: 9500 mg/kg ARZNAD 22,711,72
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Acute Tox. 4 Oral

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 6 Einträge

M - Musculo-skeletal system

A - Alimentary tract and metabolism

R - Respiratory system

G - Genito urinary system and sex hormones

M - Musculo-skeletal system

QA - Alimentary tract and metabolism

Protein BindingBenzydamine exhibits < 20% plasma protein binding after oral administration.
Pharmacodynamics · 1 Eintrag

Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) designed to elicit local anesthetic and analgesic effects mainly for the mouth and throat. It specifically acts on the local mechanisms of inflammation such as pain, oedema, or granuloma. Typically applied topically, the drug demonstrates anti-inflammatory activity reducing oedema as well as exudate and granuloma formation. Moreover, benzydamine exhibits analgesic properties and local anaesthetic activity if pain is caused by an inflammatory condition. Benzydamine can be absorbed into the oral mucosa and intact skin. Once absorbed in the local area of pain or inflammation, benzydamine binds selectively to local inflamed tissues, usually allowing it to act with few adverse systemic effects. On average a period of 2 to 4 hours is necessary for the substance to reach peak plasma concentration. Benzydamine can be synthesized with the reaction of the N-benzyl derivative from methyl anthranilate with nitrous acid to give N-nitoso derivative. This is next reduced by sodium thiosulfate to give transient hydrazine. This hydrazine can then undergo spontaneous internal hydrazide formation. Treating this resultant enolate with 3-chloro-1-dimethylamkino propane ultimately yields benzydamine.

Mechanism of Action · 1 Eintrag

Despite being categorized as a non-steroidal anti-inflammatory drug (NSAID), benzydamine demonstrates various mechanisms of action that differ from those of traditional aspirin-like NSAIDs. In particular, benzydamine predominantly acts by inhibiting the synthesis of pro inflammatory cytokines like tumour necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) without largely affecting other pro inflammatory cytokines (ie. such as IL-6 and IL-8) or anti-inflammatory cytokines (ie. like IL-10 or IL-1 receptor antagonist). Moreover, benzydamine is largely a weak inhibitor of prostaglandin synthesis as it has been shown to effectively inhibit cyclooxygenase (COX) and lipoxygenase enzyme activity only at concentrations of 1mM or greater. Considering most contemporary usages of benzydamine are topical applications that are generally not well absorbed through the skin and/or non-specialized mucosae, benzydamine does not often achieve the kind of absorption or blood concentrations necessary to cause any extraneous distant systemic effects or COX inhibition, allowing it to localize its action. Additionally, it is also hypothesized that benzydamine is capable of inhibiting the oxidative burst of neutrophils and membrane stabilization. These actions are exhibited by the substance’s ability to inhibit the release of granules from neutrophils and to stabilize lysosomes. Furthermore, benzydamine is capable of a local anaesthetic effect that may be related to its capability for inhibiting the release of inflammatory mediators like substance P and calcitonin gene related peptide from sensory nerve endings. Since substance P is capable of causing the release of histamine from mast cells, benzydamine’s prevention of substance P release further contributes to an anti-inflammatory effect. Benzydamine also demonstrates a non-specific antibacterial activity against various bacterial strains that are resistant to broad-spectrum antibiotics such as ampicillin, chloramphenicol, and tetracycline at concentrations of about 3 mmol/L. Combinatorial use of benzydamine and other antibiotics like tetracycline and chloramphenicol are also synergistic against antibiotic resistant strains of *Staphylococcus aureus* and *Pseudomonas aeruginosa*.

Zugehörige Reaktionen

1
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1658823
HRID 1658823als Produktals Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
642-72-8
PubChem CID
12555
DTXSID
DTXSID7047859
ChEMBL
CHEMBL12610
ChEBI
CHEBI:94563
UNII
4O21U048EF
EC Number
211-388-8
Nikkaji
J7.060B
storage temp.
Refrigerator
Löslichkeit
Chloroform (Sparingly), Methanol (Slightly)
Aggregatzustand
Oil
pka
9.25 · 9.25±0.28(Predicted)
Farbe
Orange
InChI
1S/C19H23N3O.ClH/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16;/h3-7,9-12H,8,13-15H2,1-2H3;1H
InChIKey
HNNIWKQLJSNAEQ-UHFFFAOYSA-N
SMILES
[Cl-].[N+H](CCCOc1n[n](c3c1cccc3)Cc2ccccc2)(C)C
CAS Datenbank
642 · 642-72-8(CAS DataBase Reference)
NIST chemische Informationen
1 · 1-Propanamine, n,n-dimethyl-3-[[1-(phenylmethyl)-1h-indazol-3-yl]oxy]-(642-72-8)
Biological Half-LifeApproximately 13 h after oral administration, with a terminal half life of about 7.7 h.
Metabolism/Metabolites · 1 Eintrag

Benzydamine is primarily metabolized by oxidation, dealkylation, and conjugation into hydroxy, dealkylated, and N-oxide metabolites. In general, however, when used at the recommended doses the levels at which benzydamine is absorbed or exposed into the body are usually not sufficient to produce systemic pharmacological effects [L

MeSH Pharmacological ClassificationSubstances that reduce or suppress INFLAMMATION.
Absorption, Distribution and Excretion · 4 Einträge

Oral doses of benzydamine are well absorbed and plasma drug concentrations reach a peak fairly rapidly and then decline with a half-life of approximately 13 hours. When applied topically, although the local drug concentrations are relatively large, the systemic absorption of topically applied benzydamine is relatively low compared to oral doses. This low topical absorption contributes to a decreased potential for any systemic drug side-effects when benzydamine is administered in this way.

The relatively high lipid solubility of the weak base benzydamine is thought to be associated with considerable passive resorption within the renal tubule, which suggests that only approximately 5% of benzydamine is excreted unchanged in the urine. At the same time however, other studies have suggested that considerably larger amounts (50-65%) of the drug is excreted unchanged in urine. While several inactive oxidized metabolites of benzydamine are excreted in urine, the benzydamine N-oxide metabolite can remain in plasma and demonstrate a half-life that is longer than the parent benzydamine compound. Nevertheless, it is generally believed that excretion occurs mainly through urine and is mostly in the form of inactive metabolites or conjugation products.

The volume of distribution of benzydamine is 10 L.

Benzydamine demonstrateas a systemic clearance of 170 ml/min.

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >50
Use ClassificationPharmaceuticals
Anwendungen · 2 Einträge

BeschreibungBenzydamine is an analytical reference standard categorized as an analgesic. Benzydamine has been abused and is associated with hallucinations, muscle weakness, and excitability. This product is intended for research and forensic applications.

VerwendenAnalgesic; antipyretic; anti-inflammatory.

Vor- und nachgelagerte Produkte

Nachgelagerte Produkte

N,N-Dimethyl-3-((1-(phenylmethyl)-1H-indazol-3-yl)oxy)-1-propanamin-monohydrochlorid